Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Medical Research Archives

Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

JVJuan C. VasquezRBRanjit S. BindraSGSusan Gueble

Discussion

Loading...

Member takes

Overview

Review discusses resistance mechanisms and highlights KL-50's potential against MGMT promoter-methylated gliomas.

Key Points

  • Grade 4 glioblastoma is highly aggressive and typically has a median survival of only 15 months.
  • About 50% of GBMs and 70-80% of anaplastic gliomas exhibit MGMT promoter methylation, leading to treatment responsiveness.
  • New compound KL-50 shows promise in overcoming resistance to temozolomide driven by loss of mismatch repair.
  • Current therapies face significant challenges, requiring innovative DNA modifiers to enhance treatment efficacy.

Cite This Study

Vasquez et al. (2025) studied this question.

synapsesocial.com/papers/68e02f3cf0e39f13e7fa2675https://doi.org/10.18103/mra.v13i9.6944
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma2025 · 9 citations
  2. 2MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy2025
  3. 3Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics2025
  4. 4The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma2025 · 4 citations
  5. 5MOLECULAR MARKERS IN PREDICTING THE OUTCOME OF DIFFUSE GLIOMA GRADE 4 TREATMENT2025